CD388 not checked
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · MK-1406
FollowEvery change as it happens, and a Monday email
Trials
4 active
7 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MK-1406 liquid for injection administered subcutaneously (SC)”In the company’s words, NCT07159763 on ClinicalTrials.gov
- Tested for
- Influenza
- Main trialPhase 3
- “Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406…”In the company’s words, NCT07159763 on ClinicalTrials.gov
- Other names
- MK-1406
Other drugs for Influenza
- MRNA-1018-H5Moderna · Phase 3
- Baloxavir MarboxilRoche · Phase 3
- BRC-201Boryung Biopharma Co., Ltd. · Phase 3
- Dipyrone monohydrateBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- MRNA Seasonal Flu vaccineGSK · Phase 3
- GP681Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Phase 3
Coming up4
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 5 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 2 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovCompletion date moved: 2027-06-30 to 2027-07-02 · ClinicalTrials.gov NCT07159763
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 2 Jul 2027 | A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | |
| Phase 2Active, not recruiting | 31 Jul 2027 | A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) | |
| Phase 1Recruiting | 31 Dec 2026 | A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) | |
| Phase 1Recruiting | 5 Feb 2027 | A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008) | |
| Phase 2Completed | 17 Jul 2023 | The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults | |
| Phase 1Completed | 14 Jul 2023 | Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects | |
| Phase 1Completed | 27 Oct 2023 | Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026